BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

Appeals court upholds Enbrel patents  Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11 billion to the company’s market cap, after the U.S. Court of Appeals for the Federal Circuit upheld a 2019...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

Hua announced Phase III follow-up data showing its first-in-class diabetes therapy led to sustained HbA1c reductions at one year -- a long-term effect that EVP and CFO George Lin told BioCentury hasn’t been observed with...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

A team of gene therapy veterans from the likes of Sangamo, Spark and AveXis have debuted Kriya with an untranched $80.5 million series A round to bring gene therapies to patients with prevalent and severe...
BioCentury | Feb 10, 2020
Product Development

vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from a Phase II trial of the company’s glucokinase activator to treat Type I diabetes could portend further success in...
BC Extra | Nov 13, 2019
Clinical News

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
BC Week In Review | Feb 8, 2019
Clinical News

Hua starts U.S. Phase I trial of diabetes candidate

Hua Medicine Ltd. (HKEX:2552) began a Phase I trial of its dorzagliatin (sinogliatin, HMS5552, RO5305552) in combination with Januvia sitagliptin in patients with Type II diabetes. The open-label, U.S. trial will evaluate the pharmacokinetic and...
BioCentury | Sep 15, 2018

Hua’s institutional advantage

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst...
BC Week In Review | Sep 14, 2018
Financial News

Hua raises $110.5M in HK IPO, trades flat on first day

Hua Medicine Ltd. (HKSE:2552) shares ended the day unchanged at HK$8.28 in the company's first day of trading Sept. 14. The diabetes play raised HK$867 million ($110.5 million) in an IPO through the sale of...
Items per page:
1 - 10 of 111